Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Johnson JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-215,600Price:--
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Johnson JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:215,600Price:$1.99
-
Mar 15, 2024 (filed on Apr 11, 2024)Insider Name:Sherman Jeffrey WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:6,502Price:--
-
Mar 15, 2024 (filed on Apr 01, 2024)Insider Name:Kong GarhengOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:6,474Price:--
-
Mar 15, 2024 (filed on Apr 01, 2024)Insider Name:Johnson JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:89,571Price:--
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Schmid John P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:4,500Price:$2.16
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Pieper StevenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:450,000Price:--
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Shannon John Patrick JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:750,000Price:--
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Johnson Kenneth ErlandOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:175,000Price:--
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Hecht BethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:750,000Price:--
Filings by filing date
-
Mar 15, 2024 (filed on Apr 11, 2024)Insider Name:Sherman Jeffrey WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:6,502Price:--
-
Mar 15, 2024 (filed on Apr 01, 2024)Insider Name:Kong GarhengOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:6,474Price:--
-
Mar 15, 2024 (filed on Apr 01, 2024)Insider Name:Johnson JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:89,571Price:--
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Johnson JohnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-215,600Price:--
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Johnson JohnOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:215,600Price:$1.99
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Schmid John P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:4,500Price:$2.16
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Pieper StevenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:450,000Price:--
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Shannon John Patrick JrOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:750,000Price:--
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Johnson Kenneth ErlandOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:175,000Price:--
-
Jan 31, 2024 (filed on Jan 31, 2024)Insider Name:Hecht BethOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:750,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1375 West Fulton Street, Suite 1300 CHICAGO IL 60607 |
Tel: | 1-844-4455704 |
Website: | https://www.xerispharma.com |
IR: | See website |
Key People | ||
Paul Raymond Edick Chairman of the Board, Chief Executive Officer | John P. Shannon President, Chief Operating Officer | Steven M. Pieper Chief Financial Officer |
Kenneth Erland Johnson Senior Vice President - Global Development and Medical Affairs | Steven Prestrelski Chief Scientific Officer | Beth P. Hecht Chief Legal Officer, Corporate Secretary |
Business Overview |
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients' lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications. |
Financial Overview |
For the fiscal year ended 31 December 2023, Xeris Biopharma Holdings Inc revenues increased 49% to $163.9M. Net loss decreased 34% to $62.3M. Revenues reflect Product revenue -Recorlev segment increase from $7.4M to $29.5M, Product revenue - Gvoke segment increase of 28% to $67M. Lower net loss reflects Change in fair value of contingent value increase from $3.2M (expense) to $5.2M (income). |
Employees: | 377 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $377.92M as of Dec 31, 2023 |
Annual revenue (TTM): | $163.91M as of Dec 31, 2023 |
EBITDA (TTM): | -$31.57M as of Dec 31, 2023 |
Net annual income (TTM): | -$62.26M as of Dec 31, 2023 |
Free cash flow (TTM): | -$49.29M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $118.48M as of Dec 31, 2023 |
Shares outstanding: | 148,253,615 as of Apr 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |